EMJ Hematology 3 [ePrint] . 2015

| View in Fullscreen

Journal Info

The meeting was introduced by Prof Robin Foà who spoke about the difficulties for patients accessing therapies in the context of rising healthcare costs and reduced budgets. Dr Mark McCamish then explained the biosimilar development process and the analytical techniques involved. Prof Felix Keil discussed the role of biosimilar medicines in haematology using the example of GP2013/rituximab (RTX), and Ms Karen Van Rassel of the Lymphoma Coalition presented the role a patient organisation can play when working with the physician to support a patient’s questions and concerns regarding lymphoma.